Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $1.3 million.

  • Heron Therapeutics' Free Cash Flow fell 5472.79% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.1 million, marking a year-over-year decrease of 24698.61%. This contributed to the annual value of -$24.2 million for FY2024, which is 5983.19% up from last year.
  • As of Q3 2025, Heron Therapeutics' Free Cash Flow stood at $1.3 million, which was down 5472.79% from -$11.1 million recorded in Q2 2025.
  • Heron Therapeutics' Free Cash Flow's 5-year high stood at $2.9 million during Q3 2024, with a 5-year trough of -$63.3 million in Q2 2021.
  • Its 5-year average for Free Cash Flow is -$24.1 million, with a median of -$25.1 million in 2023.
  • Examining YoY changes over the last 5 years, Heron Therapeutics' Free Cash Flow showed a top increase of 12948.26% in 2024 and a maximum decrease of 66317.46% in 2024.
  • Over the past 5 years, Heron Therapeutics' Free Cash Flow (Quarter) stood at -$45.6 million in 2021, then increased by 16.87% to -$37.9 million in 2022, then soared by 105.81% to $2.2 million in 2023, then plummeted by 663.17% to -$12.4 million in 2024, then skyrocketed by 110.72% to $1.3 million in 2025.
  • Its Free Cash Flow was $1.3 million in Q3 2025, compared to -$11.1 million in Q2 2025 and -$9.0 million in Q1 2025.